Treatment of Cerebrospinal Fluid Shunt Infections with Teicoplanin

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 1994 Dec 1

PMID 7889968

Citations 2

Authors

M L Fernandez Guerrero

M de Gorgolas

R Fernandez Roblas

J M Campos

Affiliations

Soon will be listed here.

Abstract

Intraventricular teicoplanin 10-15 mg was administered daily to three patients with cerebrospinal fluid (CSF) shunt infections due to Staphylococcus epidermidis and Enterococcus faecalis. Teicoplanin concentrations in CSF 24 h after intrathecal injection of the drug exceeded four- to eight-fold the MICs for the infecting microorganisms. CSF cultures rapidly became negative and shunt devices were withdrawn and replaced in the same operative procedure. Intraventricular teicoplanin was well tolerated. No relapses occurred. Teicoplanin may be an alternative to vancomycin for the antimicrobial therapy of CSF shunt infections.

Citing Articles

Intrathecal Antibacterial and Antifungal Therapies.

Nau R, Blei C, Eiffert H Clin Microbiol Rev. 2020; 33(3).

PMID: 32349999 PMC: 7194852. DOI: 10.1128/CMR.00190-19.

Reinfection following initial cerebrospinal fluid shunt infection.

Simon T, Hall M, Dean J, Kestle J, Riva-Cambrin J J Neurosurg Pediatr. 2010; 6(3):277-85.

PMID: 20809713 PMC: 2953872. DOI: 10.3171/2010.5.PEDS09457.

References

Venditti M, Micozzi A, Serra P, BUNIVA G, Palma L, Martino P . Intraventricular administration of teicoplanin in shunt associated ventriculitis caused by methicillin resistant Staphylococcus aureus. J Antimicrob Chemother. 1988; 21(4):513-5. DOI: 10.1093/jac/21.4.513. View

Maserati R, Cruciani M, Azzini M, Carnevale C, Suter F, Concia E . Teicoplanin in the therapy of staphylococcal neuroshunt infections. Int J Clin Pharmacol Res. 1987; 7(3):207-13. View

Cruciani M, Navarra A, Di Perri G, Andreoni M, Danzi M, Concia E . Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections. Clin Infect Dis. 1992; 15(2):285-9. DOI: 10.1093/clinids/15.2.285. View

De Lalla F, Santoro D, Rinaldi E, Suter F, Cruciani M, Guaglianone M . Teicoplanin in the treatment of infections by staphylococci, Clostridium difficile and other gram-positive bacteria. J Antimicrob Chemother. 1989; 23(1):131-42. DOI: 10.1093/jac/23.1.131. View

Calain P, Krause K, Vaudaux P, Auckenthaler R, Lew D, Waldvogel F . Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis. 1987; 155(2):187-91. DOI: 10.1093/infdis/155.2.187. View

Schoenbaum S, Gardner P, Shillito J . Infections of cerebrospinal fluid shunts: epidemiology, clinical manifestations, and therapy. J Infect Dis. 1975; 131(5):543-52. DOI: 10.1093/infdis/131.5.543. View

Glupczynski Y, Lagast H, Van der Auwera P, Thys J, Crokaert F, Yourassowsky E . Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 1986; 29(1):52-7. PMC: 180363. DOI: 10.1128/AAC.29.1.52. View

Stahl J, Croize J, Wolff M, Garaud J, Leclercq P, Vachon F . Poor penetration of teicoplanin into cerebrospinal fluid in patients with bacterial meningitis. J Antimicrob Chemother. 1987; 20(1):141-2. DOI: 10.1093/jac/20.1.141. View

McLaurin R, Frame P . Treatment of infections of cerebrospinal fluid shunts. Rev Infect Dis. 1987; 9(3):595-603. DOI: 10.1093/clinids/9.3.595. View

10.

Frame P, McLaurin R . Treatment of CSF shunt infections with intrashunt plus oral antibiotic therapy. J Neurosurg. 1984; 60(2):354-60. DOI: 10.3171/jns.1984.60.2.0354. View

11.

Bibler M, Frame P, Hagler D, Bode R, Staneck J, Thamlikitkul V . Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections. Antimicrob Agents Chemother. 1987; 31(2):207-12. PMC: 174693. DOI: 10.1128/AAC.31.2.207. View